Table 2. Treatment history at initiation of Imatinib treatment for newly diagnosed patients with CML in Ethiopia, from October 1, 2016- November 30, 2017.
| Base line Findings at Initiation of Imatinib | Median (Ranges) | N | % | ||
|---|---|---|---|---|---|
| Treatment History | |||||
| For Cytoreduction treatment | |||||
| HU* | 136 | 92.5 | |||
| No (directly started IMa treatment) | 11 | 7.5 | |||
| Duration of HU treatment, In months | 1.0 (0–9.5) | ||||
| Latency of Initiation of IM therapy | 1.5(0.5–12.0) | ||||
| Initial daily Dose (IM) | |||||
| 400 mg | 141 | 95.9 | |||
| 600 mg | 6 | 4.1 | |||
| IM + HU combination treatment | |||||
| Yes | 36 | 24.5 | |||
| No | 111 | 76.5 | |||
| Duration of combination, in months | 0.5(0.5–2) | ||||
*Hydroxyurea
a Imatinib